Similar articles for PMID: 15701267

Year	Number of Results
1992	3
1994	5
1995	5
1996	5
1997	4
1998	3
1999	4
2000	5
2001	10
2002	6
2003	6
2004	6
2005	2
2006	4
2007	11
2008	3
2009	5
2010	7
2011	8
2012	9
2013	5
2014	6
2015	6
2016	3
2017	3
2018	2
2019	4
2020	6
2021	8
2022	3
2023	2
2024	0

1

Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.

Packianathan S, Mehta RG, Mehta RR, Hall WH, Boerner PS, Beckett LA, Vijayakumar S. Packianathan S, et al. Cancer J. 2004 Nov-Dec;10(6):357-67. doi: 10.1097/00130404-200411000-00005. Cancer J. 2004. PMID: 15701267

2

Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.

Lieberman R. Lieberman R. Urology. 2001 Apr;57(4 Suppl 1):224-9. doi: 10.1016/s0090-4295(00)00981-x. Urology. 2001. PMID: 11295633

3

Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.

Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Steele VE, Lubet RA, Sigman CC. Kelloff GJ, et al. J Cell Biochem Suppl. 1995;23:1-9. doi: 10.1002/jcb.240590902. J Cell Biochem Suppl. 1995. PMID: 8747372 Review.

4

Design considerations for efficient prostate cancer chemoprevention trials.

Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Lee JJ, et al. Urology. 2001 Apr;57(4 Suppl 1):205-12. doi: 10.1016/s0090-4295(00)00976-6. Urology. 2001. PMID: 11295629

5

Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials.

Trock BJ. Trock BJ. Urology. 2001 Apr;57(4 Suppl 1):241-7. doi: 10.1016/s0090-4295(00)00983-3. Urology. 2001. PMID: 11295636

6

Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.

Greenwald P. Greenwald P. J Cell Biochem Suppl. 1996;25:29-36. J Cell Biochem Suppl. 1996. PMID: 9027595 Review.

7

Models for early chemoprevention trials in breast cancer.

Fabian CJ, Kimler BF, Elledge RM, Grizzle WE, Beenken SW, Ward JH. Fabian CJ, et al. Hematol Oncol Clin North Am. 1998 Oct;12(5):993-1017. doi: 10.1016/s0889-8588(05)70038-1. Hematol Oncol Clin North Am. 1998. PMID: 9888018 Review.

8

Chemoprevention of prostate cancer: concepts and strategies.

Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovitch L, Malone WA, Crowell JA, Sigman CC. Kelloff GJ, et al. Eur Urol. 1999;35(5-6):342-50. doi: 10.1159/000019906. Eur Urol. 1999. PMID: 10325487 Review.

9

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.

Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Lieberman R, et al. Urology. 2001 Apr;57(4 Suppl 1):4-27. doi: 10.1016/s0090-4295(00)00931-6. Urology. 2001. PMID: 11295590

10

Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.

Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Sigman CC. Kelloff GJ, et al. Cancer Res. 1994 Apr 1;54(7 Suppl):2015s-2024s. Cancer Res. 1994. PMID: 8137331 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

147 results

Results by year